| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2011.38.4032 |
| P698 | PubMed publication ID | 22547592 |
| P50 | author | Igor N. Bondarenko | Q30957829 |
| Piotr Serwatowski | Q114456257 | ||
| P2093 | author name string | Martin Reck | |
| Thomas J Lynch | |||
| Fabrice Barlesi | |||
| Haolan Lu | |||
| Martin Sebastian | |||
| Jean-Marie Cuillerot | |||
| Joel Neal | |||
| Raju Chacko | |||
| Alexander Luft | |||
| P2860 | cites work | CTLA-4 can function as a negative regulator of T cell activation | Q28235866 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| lung cancer | Q47912 | ||
| paclitaxel | Q423762 | ||
| ipilimumab | Q2459042 | ||
| carboplatin | Q415588 | ||
| P304 | page(s) | 2046-2054 | |
| P577 | publication date | 2012-04-30 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study | |
| P478 | volume | 30 |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q91637377 | A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing |
| Q57025289 | A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization |
| Q95319497 | A guide to cancer immunotherapy: from T cell basic science to clinical practice |
| Q37178662 | A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma |
| Q99582721 | A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians |
| Q47155204 | A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells |
| Q33710008 | A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer |
| Q38390183 | A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors |
| Q28087576 | A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |
| Q37559487 | Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q38748185 | Adapting conventional cancer treatment for immunotherapy |
| Q47252744 | Adaptive Resistance to Cancer Immunotherapy |
| Q38397760 | Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer |
| Q42331916 | Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war! |
| Q37680966 | Advances in Immunotherapy for Glioblastoma Multiforme |
| Q61807295 | Advances in immune checkpoint inhibitors for bone sarcoma therapy |
| Q26778790 | Advances in immunotherapy for treatment of lung cancer |
| Q38127786 | Advances in personalized therapy for lung cancer |
| Q41790713 | An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. |
| Q38647794 | An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection |
| Q46046777 | Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824). |
| Q58567297 | Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer |
| Q36106006 | Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. |
| Q47104348 | Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. |
| Q31104000 | Antibody Therapies in Cancer |
| Q39000185 | Antibody therapeutics for treating prostate cancer: where are we now and what comes next? |
| Q91765656 | Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis |
| Q92068238 | Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma |
| Q38435967 | Best practice in the treatment of advanced squamous cell lung cancer |
| Q38072813 | Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer |
| Q34487689 | Big opportunities for small molecules in immuno-oncology |
| Q48320507 | Biology and evolution of poorly differentiated neuroendocrine tumors |
| Q33862861 | Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer |
| Q42723974 | CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany |
| Q36546997 | COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. |
| Q42683596 | CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases |
| Q47424017 | CTLA-4: a moving target in immunotherapy. |
| Q38252348 | CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? |
| Q48234959 | Can checkpoint inhibitor therapy improve response to chemotherapy? |
| Q37098427 | Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease |
| Q35668604 | Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q26769757 | Cancer stem cells and immunoresistance: clinical implications and solutions |
| Q38225574 | Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. |
| Q38935027 | Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic |
| Q36130505 | Cellular and molecular immunology of lung cancer: therapeutic implications. |
| Q36295004 | Checkpoint Blockade in Lung Cancer and Mesothelioma |
| Q26745442 | Checkpoint Inhibitors and Their Application in Breast Cancer |
| Q38611369 | Checkpoint blockade in combination with cancer vaccines |
| Q38274609 | Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. |
| Q90681722 | Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials |
| Q38079749 | Chemoimmunotherapy: reengineering tumor immunity |
| Q95260508 | Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer? |
| Q38838014 | Chemotherapy remains an essential element of personalized care for persons with lung cancers |
| Q48535444 | Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy |
| Q38636430 | Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. |
| Q34669751 | Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types |
| Q38262593 | Clinical impact of checkpoint inhibitors as novel cancer therapies |
| Q36336136 | Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer |
| Q57799745 | Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer |
| Q49342746 | ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors |
| Q41831841 | Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors |
| Q37369239 | Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q38645178 | Combination cancer immunotherapies tailored to the tumour microenvironment |
| Q52718920 | Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? |
| Q49188022 | Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). |
| Q64248558 | Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System |
| Q64077050 | Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer |
| Q39143599 | Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity |
| Q47621538 | Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. |
| Q38447992 | Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? |
| Q55430629 | Combining immunotherapy and radiotherapy in lung cancer. |
| Q26991721 | Combining radiation and immunotherapy: a new systemic therapy for solid tumors? |
| Q41143313 | Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review |
| Q64298027 | Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis |
| Q98289189 | Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis |
| Q64264629 | Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials |
| Q58576344 | Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis |
| Q64228114 | Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials |
| Q38752269 | Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. |
| Q28274701 | Comprehensive genomic characterization of squamous cell lung cancers |
| Q55314488 | Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. |
| Q64241978 | Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis |
| Q26783432 | Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy |
| Q47878958 | Current and emerging EGFR therapies for glioblastoma. |
| Q38848990 | Current and future immunotherapeutic approaches in Hodgkin lymphoma |
| Q38108501 | Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). |
| Q59135385 | Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges |
| Q33645595 | Current state of immunotherapy for non-small cell lung cancer |
| Q38492833 | Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology |
| Q38577834 | Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade |
| Q39384263 | DNA Damage and Repair Biomarkers of Immunotherapy Response |
| Q52690105 | Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. |
| Q37100703 | Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer |
| Q36821101 | Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. |
| Q37088281 | Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements |
| Q50885033 | Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. |
| Q37542216 | Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma |
| Q64114283 | Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib |
| Q26786594 | Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population |
| Q55375458 | Do immune checkpoint inhibitors need new studies methodology? |
| Q34778819 | Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells |
| Q59791950 | Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis |
| Q55709749 | Efficacy and immune activation of ipilimumab in early-stage lung cancer patients. |
| Q40163076 | Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. |
| Q34953043 | Efficacy of combined therapy with paclitaxel and low-level ultrasound in human chronic myelogenous leukemia cell line K562. |
| Q38306880 | Emerging drugs for squamous cell lung cancer |
| Q38254083 | Emerging drugs targeting PD-1 and PD-L1: reality or hope? |
| Q38584979 | Emerging immune checkpoints for cancer therapy |
| Q38184650 | Emerging immunotherapy strategies in breast cancer |
| Q37031656 | Emerging options for the treatment of melanoma - focus on ipilimumab |
| Q28069422 | Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis |
| Q34659806 | Emerging therapies for adult soft tissue sarcoma. |
| Q26851802 | Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses |
| Q38673109 | Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer |
| Q60953071 | Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity |
| Q40018639 | Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma |
| Q37350763 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab |
| Q53060188 | Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. |
| Q38523302 | Evolving Concepts: Immunity in Oncology from Targets to Treatments |
| Q38553010 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. |
| Q64080822 | Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing |
| Q26779184 | Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy |
| Q38246950 | Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer |
| Q52576596 | First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. |
| Q92968414 | First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis |
| Q64097975 | First-line management of metastatic non-small cell lung cancer: An Indian perspective |
| Q64926460 | First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis. |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q26778793 | Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors |
| Q37082763 | Fundamental effects of PD-1 antibody on the body: a brief report |
| Q37269005 | Genomic landscape of DNA repair genes in cancer |
| Q38839148 | HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy |
| Q37340543 | Harnessing immune responses in the tumor microenvironment: all signals needed |
| Q33729072 | Hispanic accrual on randomized cancer clinical trials: a call to arms |
| Q47120953 | How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know |
| Q33793930 | Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene |
| Q45959320 | Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. |
| Q26830509 | Immune Checkpoint Blockade in Cancer Therapy |
| Q38916160 | Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. |
| Q26795509 | Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer |
| Q50021106 | Immune Checkpoint Blockade: The New Frontier in Cancer Treatment |
| Q90173973 | Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State |
| Q38830398 | Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer |
| Q38548889 | Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy |
| Q26796309 | Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy |
| Q38669273 | Immune Therapy |
| Q28069864 | Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma |
| Q38899873 | Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer |
| Q38878902 | Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies |
| Q28083981 | Immune checkpoint blockade: a common denominator approach to cancer therapy |
| Q34406469 | Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? |
| Q38878906 | Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges |
| Q38856570 | Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer |
| Q34437570 | Immune checkpoint inhibitors in NSCLC. |
| Q47563451 | Immune checkpoint inhibitors in advanced non-small cell lung cancer |
| Q26775383 | Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities |
| Q38806038 | Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers |
| Q38791209 | Immune checkpoint inhibitors in lung cancer: past, present and future |
| Q94355616 | Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol |
| Q38207907 | Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer |
| Q47400647 | Immune checkpoint inhibitors: new strategies to checkmate cancer |
| Q26738359 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment |
| Q95933555 | Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma |
| Q38727542 | Immune checkpoint therapy for non-small-cell lung cancer: an update |
| Q38172521 | Immune evasion in acute myeloid leukemia: current concepts and future directions |
| Q34686944 | Immune modulation for cancer therapy |
| Q38159801 | Immune modulation in cancer with antibodies |
| Q26853248 | Immune therapies for lung cancer |
| Q39009781 | Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors |
| Q41356383 | Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients |
| Q91905605 | Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis |
| Q46694815 | Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review |
| Q39332694 | Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review |
| Q30235360 | Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review |
| Q37516943 | Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients |
| Q49668388 | Immune-related tumor response assessment criteria: a comprehensive review |
| Q39044147 | Immuno-Oncology: The Third Paradigm in Early Drug Development |
| Q42421273 | Immuno-oncology combinations: raising the tail of the survival curve |
| Q94526295 | Immuno-oncology-the new paradigm of lung cancer treatment |
| Q38424617 | Immuno-regulatory antibodies for the treatment of cancer |
| Q38733611 | ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. |
| Q41056243 | Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models |
| Q57497508 | Immunogenic effects of chemotherapy-induced tumor cell death |
| Q92616105 | Immunological Agents Used in Cancer Treatment |
| Q60548670 | Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect |
| Q38646993 | Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics |
| Q38230278 | Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines |
| Q38687631 | Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future |
| Q38587157 | Immunotherapies for bladder cancer: a new hope. |
| Q38721253 | Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives |
| Q26866513 | Immunotherapy advances for glioblastoma |
| Q38549542 | Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights |
| Q38286376 | Immunotherapy and lung cancer: current developments and novel targeted therapies |
| Q38265555 | Immunotherapy for Lung Cancer: Has it Finally Arrived? |
| Q26751254 | Immunotherapy for lung cancer |
| Q26750617 | Immunotherapy for lung cancer: advances and prospects |
| Q38367414 | Immunotherapy for lung cancer: for whom the bell tolls? |
| Q38154289 | Immunotherapy for lung cancer: ongoing clinical trials |
| Q38259571 | Immunotherapy for non-small cell lung cancer. |
| Q52938218 | Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? |
| Q36852170 | Immunotherapy for non-small cell lung cancer: current concepts and clinical trials |
| Q38514566 | Immunotherapy for non-small-cell lung cancer: the past 10 years |
| Q96228878 | Immunotherapy for platinum-resistant ovarian cancer |
| Q38930370 | Immunotherapy in Lung Cancer |
| Q56896166 | Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies |
| Q51092888 | Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. |
| Q38390093 | Immunotherapy in lung cancer |
| Q51132444 | Immunotherapy in lung cancer. |
| Q55073226 | Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. |
| Q36691818 | Immunotherapy in pediatric malignancies: current status and future perspectives |
| Q27000382 | Immunotherapy in the treatment of non-small cell lung cancer |
| Q40099075 | Immunotherapy of cancers comes of age. |
| Q38390104 | Immunotherapy prospects in the treatment of lung cancer and mesothelioma |
| Q38699858 | Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms |
| Q91714375 | Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept |
| Q38242271 | Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? |
| Q47652834 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer |
| Q41861892 | Improving drug uptake and penetration into tumors: current and forthcoming opportunities. |
| Q38543250 | In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment |
| Q92535665 | Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies |
| Q60923000 | Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis |
| Q55425422 | Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. |
| Q95271900 | Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer |
| Q30674996 | Inferring tumour purity and stromal and immune cell admixture from expression data |
| Q39017623 | Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? |
| Q34951157 | Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma |
| Q37131014 | Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management |
| Q36999978 | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study |
| Q56897633 | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial |
| Q38202161 | Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. |
| Q30240751 | Ipilimumab: from preclinical development to future clinical perspectives in melanoma |
| Q37994189 | Ipilimumab: its potential in non-small cell lung cancer |
| Q40223999 | KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma |
| Q40394041 | Les inhibiteurs des points de contrôle immunitaire dans le cancer bronchique non à petites cellules de stade avancé. |
| Q52372679 | Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. |
| Q36946100 | Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. |
| Q92642710 | Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin |
| Q38366141 | Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role? |
| Q39027394 | Lung Cancer Biomarkers |
| Q38830349 | Lung Cancer Staging and Prognosis. |
| Q45459148 | Lung Cancer Subtypes Generate Unique Immune Responses |
| Q28075788 | Lung cancer in the Indian subcontinent |
| Q36328370 | Lung cancer: Biology and treatment options |
| Q88318229 | Lung cancer: First-line immunotherapy in lung cancer - taking the first step |
| Q38181691 | Lung cancer: potential targets for immunotherapy |
| Q36891038 | Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance |
| Q41113415 | Macrophages, Inflammation, and Lung Cancer |
| Q38131165 | Management of non-small-cell lung cancer: recent developments |
| Q26740288 | Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer |
| Q51104725 | Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. |
| Q39101223 | Meta-analysis of the risk of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 therapies |
| Q38901338 | Metastatic melanoma and immunotherapy |
| Q39321633 | Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q38358410 | Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). |
| Q38104670 | Molecular-targeted agents combination therapy for cancer: developments and potentials |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q38666241 | Monitoring immune-checkpoint blockade: response evaluation and biomarker development |
| Q38253815 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. |
| Q38067454 | Monoclonal antibodies in lung cancer |
| Q100513877 | Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma |
| Q38245669 | Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer |
| Q50321985 | Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. |
| Q35059990 | NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy |
| Q39183391 | Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. |
| Q35869292 | Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. |
| Q46047154 | New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone |
| Q56890070 | New advances in immunotherapy for non-small cell lung cancer |
| Q38397279 | New clinical advances in immunotherapy for the treatment of solid tumours. |
| Q33704088 | New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib |
| Q26829161 | New modalities of cancer treatment for NSCLC: focus on immunotherapy |
| Q26775385 | New strategies in immunotherapy for non-small cell lung cancer |
| Q38461521 | New strategies to develop new medications for lung cancer and metastasis |
| Q38114835 | New targets in non-small cell lung cancer |
| Q90164385 | Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies |
| Q34466452 | Nivolumab in NSCLC: latest evidence and clinical potential |
| Q38541767 | Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy |
| Q26740333 | Non-small cell lung cancer: current treatment and future advances |
| Q51021428 | Non-small-cell lung cancer. |
| Q54391550 | Non-small-cell lung cancer: promising advances in treatment. |
| Q89858503 | Normalization Cancer Immunotherapy for Melanoma |
| Q90811847 | Nouvelles stratégies innovantes en immunothérapie |
| Q28071998 | Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma |
| Q38108836 | Novel antibodies targeting immune regulatory checkpoints for cancer therapy. |
| Q47936526 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies |
| Q102379531 | Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer |
| Q38953461 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer |
| Q26775388 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies |
| Q38734978 | Novel therapies for advanced squamous cell carcinoma of the lung |
| Q26775390 | Novel therapies in small cell lung cancer |
| Q38391533 | On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation |
| Q97067582 | Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO |
| Q33830113 | Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? |
| Q38073157 | Other signalization targets |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q50445792 | PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody |
| Q39033713 | PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? |
| Q38642853 | PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. |
| Q87449797 | PD-L1 in non-small-cell lung cancer: the third target for immunotherapy |
| Q36903206 | PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy |
| Q34502899 | Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment |
| Q52887713 | Pembrolizumab for the treatment of non-small cell lung cancer. |
| Q37688658 | Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives |
| Q46865924 | Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma |
| Q47130393 | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015. |
| Q35817265 | Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. |
| Q34333155 | Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer |
| Q56896949 | Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody |
| Q36318092 | Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population |
| Q93111901 | Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer |
| Q38527663 | Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. |
| Q36350628 | Prediction of cancer cell sensitivity to natural products based on genomic and chemical properties. |
| Q91828758 | Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer |
| Q26745590 | Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer |
| Q36769318 | Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer |
| Q40802902 | Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer |
| Q124854868 | Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis |
| Q36916445 | Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer |
| Q26865725 | Progress in immunotherapy for non-small cell lung cancer |
| Q28083663 | Promising targets and current clinical trials in metastatic squamous cell lung cancer |
| Q46166592 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer |
| Q36821194 | Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer. |
| Q39198154 | Prospects for combining targeted and conventional cancer therapy with immunotherapy |
| Q55000624 | Putting the brakes on CTLA-4 inhibition in lung cancer? |
| Q39017268 | Radiotherapy and immunotherapy: a beneficial liaison? |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q57823167 | Radiotherapy induces responses of lung cancer to CTLA-4 blockade |
| Q38514601 | Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. |
| Q38080047 | Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. |
| Q38099562 | Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents |
| Q28069323 | Recent Advances in Immunotherapy in Metastatic NSCLC |
| Q34290801 | Recent advances in immunotherapy for non-small-cell lung cancer |
| Q38826419 | Recent developments in the use of immunotherapy in non-small cell lung cancer |
| Q38168904 | Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer |
| Q38473314 | Regulatory T cells and potential inmmunotherapeutic targets in lung cancer |
| Q34537285 | Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome |
| Q64271422 | Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis |
| Q90642504 | Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis |
| Q38566770 | Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. |
| Q38591135 | Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. |
| Q38699309 | Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. |
| Q31171172 | Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data |
| Q50020799 | Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. |
| Q57174372 | Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer |
| Q93172097 | Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective |
| Q49549096 | Role of immune-checkpoint inhibitors in lung cancer |
| Q38443020 | Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. |
| Q38170384 | Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. |
| Q92073794 | Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer |
| Q30251438 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
| Q26775876 | Second-line combination therapies in nonsmall cell lung cancer without known driver mutations |
| Q36298852 | Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. |
| Q38661099 | Single versus combination immunotherapy drug treatment in melanoma |
| Q35836257 | Small cell lung cancer: will recent progress lead to improved outcomes? |
| Q37175437 | Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases |
| Q38749639 | Standard of care in immunotherapy trials: Challenges and considerations. |
| Q34681069 | State of the art: Response assessment in lung cancer in the era of genomic medicine |
| Q91742496 | Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review |
| Q47278600 | Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review |
| Q28486600 | Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity |
| Q37126642 | Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models |
| Q38529051 | Systematic review: colitis associated with anti-CTLA-4 therapy. |
| Q26865490 | Systemic and targeted therapies for early-stage lung cancer |
| Q92830528 | Targeted Therapies in Non-small-Cell Lung Cancer |
| Q33585089 | Targeted immunotherapy for non-small cell lung cancer |
| Q38625550 | Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives |
| Q27022852 | Targeted therapies in development for non-small cell lung cancer |
| Q36999705 | Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? |
| Q37709922 | Targeted therapy for non-small-cell lung cancer: past, present and future |
| Q37246286 | Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer |
| Q38956294 | Targeting PD-1/PD-L1 in lung cancer: current perspectives |
| Q38720801 | Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. |
| Q38128228 | Targeting the immune system in the treatment of non-small-cell lung cancer |
| Q38397629 | Targeting the immune system to treat lung cancer: rationale and clinical experience. |
| Q52740477 | The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. |
| Q26796549 | The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials |
| Q38401891 | The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System |
| Q26738677 | The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics |
| Q26786932 | The Evolution of Therapies in Non-Small Cell Lung Cancer |
| Q27022789 | The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment |
| Q52582484 | The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. |
| Q38679301 | The Microenvironment of Lung Cancer and Therapeutic Implications |
| Q53107269 | The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas. |
| Q28066568 | The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy |
| Q36169794 | The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy |
| Q47916852 | The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety |
| Q90352646 | The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review |
| Q58698737 | The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis |
| Q33434828 | The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. |
| Q28081893 | The interplay of immunotherapy and chemotherapy: harnessing potential synergies |
| Q26823305 | The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC) |
| Q38824489 | The next generation of immunotherapy: keeping lung cancer in check. |
| Q26799896 | The past, present and future of immunotherapy against tumor |
| Q46200598 | The race for combined checkpoint inhibition in NSCLC. |
| Q34917875 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. |
| Q34402325 | The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 |
| Q38875474 | The role of myeloid cells in cancer therapies |
| Q47138418 | The sexist behaviour of immune checkpoint inhibitors in cancer therapy? |
| Q42336242 | Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer |
| Q90407151 | Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response |
| Q57298272 | Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature |
| Q38739807 | Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer |
| Q26775392 | Treatment of advanced squamous cell carcinoma of the lung: a review |
| Q44807139 | Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial |
| Q38631254 | Tremelimumab for the treatment of malignant mesothelioma |
| Q28067674 | Trends and advances in tumor immunology and lung cancer immunotherapy |
| Q42847992 | Trial Watch: Anticancer radioimmunotherapy |
| Q43104064 | Trial Watch: Radioimmunotherapy for oncological indications |
| Q56932681 | Trial watch: Monoclonal antibodies in cancer therapy |
| Q37022378 | Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma |
| Q49434203 | Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer |
| Q58096039 | Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer |
| Q39239026 | Tuning cancer fate: the unremitting role of host immunity. |
| Q38205723 | Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy |
| Q24619675 | Update in lung cancer and mesothelioma 2012 |
| Q56897146 | Update on immune checkpoint inhibitors in lung cancer |
| Q37462524 | Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy |
| Q39181190 | VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy |
| Q36868927 | Venovenous perfusion-induced systemic hyperthermia: five-day sheep survival studies |
| Q39791206 | Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. |
| Q38856436 | What does the future hold for immunotherapy in cancer? |
| Q40065733 | What have we learned from cancer immunotherapy in the last 3 years? |
| Q38193716 | What is the role of chemotherapy in the treatment of melanoma? |
| Q37301472 | What lies within: novel strategies in immunotherapy for non-small cell lung cancer |
| Q36207901 | Why has active immunotherapy not worked in lung cancer? |
| Q55441788 | [Advances in immunotherapies for non-small cell lung cancer]. |
| Q54380709 | [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]. |
| Q55436672 | [Review on immunotherapies for lung cancer]. |
| Q52879625 | [The pathology of adverse events with immune checkpoint inhibitors]. |
| Q38748974 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics |
| Q37536367 | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
Search more.